γ-Amino butyric acid (GABA)-activated Clchannels are critical mediators of inhibitory postsynaptic potentials in the CNS. To date, rational design efforts to identify potent and selective GABA A subtype ligands have been hampered by the absence of suitable high-throughput screening approaches. The authors describe 384-well population patch-clamp (PPC) planar array electrophysiology methods for the study of GABA A receptor pharmacology. In HEK293 cells stably expressing human α1β3γ2 GABA A channels, GABA evoked outward currents at 0 mV of 1.05 ± 0.08 nA, measured 8 s post GABA addition. The I GABA was linear and reversed close to the theoretical E Cl (-56 mV). Concentration-response curve analysis yielded a mean pEC 50 value of 5.4 and Hill slope of 1.5, and for a series of agonists, the rank order of potency was muscimol > GABA > isoguvacine. A range of known positive modulators, including diazepam and pentobarbital, produced concentrationdependent augmentation of the GABA EC 20 response (1 µM). The competitive antagonists bicuculline and gabazine produced concentration-dependent, parallel, rightward displacement of GABA curves with pA 2 and slope values of 5.7 and 1.0 and 6.7 and 1.0, respectively. In contrast, picrotoxin (0.2-150 µM) depressed the maximal GABA response, implying a noncompetitive antagonism. Overall, the pharmacology of human α1β3γ2 GABA A determined by PPC was highly similar to that obtained by conventional patch-clamp methods. In small-scale single-shot screens, Z′ values of >0.5 were obtained in agonist, modulator, and antagonist formats with hit rates of 0% to 3%. The authors conclude that despite the inability of the method to resolve the peak agonist responses, PPC can rapidly and usefully quantify pharmacology for the α1β3γ2 GABA A isoform. These data suggest that PPC may be a valuable approach for a focused set and secondary screening of GABA A receptors and other slow ligand-gated ion channels. (Journal of Biomolecular Screening 2009:769-780) 
INTRODUCTION
γ -Amino butyric Acid (GAbA) is the principal inhibitory neurotransmitter in the mammalian CNS and acts via metabotropic GABA B and ionotropic GABA A/C receptors (for reviews, see Whiting 1 and Bowery and Smart 2 ). GABA A receptors are members of the "cys-loop" ion channel superfamily and function as fast ligand-gated Clchannels. The binding of GABA evokes a rapid conformational change that opens an integral pore to permit transmembrane Clinflux. 3, 4 In most circumstances, the net flow of Clis inward, giving rise to membrane hyperpolarization and a reduction in neuronal excitability.
The transmembrane architecture and subunit composition of GABA A channels are complex. Typically, 5 subunits, each with 4 transmembrane domains and extracellular N-termini and C-termini, assemble into a pentameric ring structure around a central pore. α 1-6 , β 1-4 , γ 1-3 , δ, ε, θ, and ρ 1-2 subunits have been identified in humans, and the stoichiometry is typically 2α, 2β, and 1γ. 3 The precise stoichiometry of receptors containing δ, ε, θ, and ρ 1-2 is currently unknown. Although not every permutation and combination of subunit exists in physiology, the number and diversity of these building blocks yield significant heterogeneity in the properties of native GABA A receptors. For example, different isoforms of the α subunit confer different sensitivities to GABA, whereas β and γ subtypes govern channel expression, desensitization kinetics, and permeability of the channel. 5 Pharmacological modulation of GABA A receptors is a clinically proven mechanism for a range of CNS indications, including anxiety, epilepsy, sleep disorders, alcohol withdrawal, and anesthesia (for review, see Nemeroff 6 ). A number of distinct and overlapping drug binding sites on GABA channels are known. Benzodiazepines (BDZs), for example, act as positive modulators of GABA A channels via an interaction at the α/γ subunit interface. It is generally accepted that the beneficial anxiolytic, myorelaxant, and cognitive effects of BDZs are mediated by α2 and α3 containing channels, whereas the undesirable sedative and dependence actions are α1 mediated. [7] [8] [9] [10] There have been widespread and extensive searches for improved, subtype-selective drugs for GABA channels, but these have been hampered by the availability of suitable highthroughput screening (HTS) and secondary hit confirmation approaches (for review, see Smith and Simpson 11 ) .
Radioligand binding assays (e.g., 3 H flunitrazepam, 3 H muscimol) have proven useful but cannot differentiate agonism/ antagonism or positive/negative modulation and, with the multitude of recognition sites, fail to provide the full picture. A range of functional assay formats exists, including Clflux measurement with either 36 Cl radioisotopes 12 or Clsensitive fluorophores such as Cl -YFP [13] [14] [15] and membrane potential readouts using voltage-sensitive probes. [16] [17] [18] These formats are valuable for high-throughput hit identification screening but are limited in secondary screens by their nonlinearity of signal, low sensitivity, and/or susceptibility to fluorescence interference. Electrophysiological methods are generally accepted as the gold standard because they allow measurement of receptormediated changes in ion flux without isotopes or fluorophores. With channels expressed in Xenopus oocytes, 2-electrode voltage-clamp methods have been semiautomated 19 to yield low-to medium-throughput assays. However, pharmacological studies in amphibian eggs are frequently compromised by poor drug access to the receptor due to the large number of invaginations in the oocyte membrane (see Goldin 20 ) and are therefore not favored.
Thus far, there has been limited progress in significantly increasing the throughput of GABA A patch-clamp studies on mammalian cells using automated electrophysiology techniques. This holds true not only for GABA A but also for other ligand-gated ion channels. A major limitation is the inability of most of the systems to rapidly apply ligands and simultaneously measure signals, as can be achieved with conventional patch-clamp techniques using U-tubes or other rapid solution switching methods. 21 Here, we have examined the use of the highest throughput automated planar array electrophysiology IonWorks system to this end. 22, 23 Although perhaps nonintuitive, given the lack of simultaneous compound addition and read functionality, empirically we find that measurements after the peak response yield a highly acceptable pharmacological profile. With the 384-well throughput of this format and the electrophysiological readout, we suggest that this approach may be valuable for a focused set and secondary screening of GABA A receptors and other slow ligand-gated ion channels.
MATERIALS AND METHODS

Cell line generation and culture
Stable cell lines coexpressing the human GABA A α1, β3, and γ2 subunits (Genbank accession numbers α1, X14766, β3 NM_000814, γ2 X15376) were generated by first cotransfecting HEK293 cells using lipofectamine and 3 separate plasmid vectors: pCIN5-GABA-Aα1, pCIH-GABA-Aβ3, and pCIP-GABA-Aγ2, which carry neomycin, hygromycin, and puromycin resistance markers, respectively. 24 A nonclonal cell population was established following selection in DMEM/F12 media (#21331-020, Invitrogen, Carlsbad, CA), supplemented with fetal bovine serum (10%, #10500-064, Invitrogen), nonessential amino acids (1%, #11140-035, Invitrogen), L-glutamine (2 mM, #25030-024, Invitrogen), geneticin G418 (0.4 mg mL -1 , #10131-027, Invitrogen), hygromycin (0.1 mg mL -1 , #10687-010, Invitrogen), and puromycin (5 µg mL -1 , #P-7255, Sigma, St. Louis, MO). Clonal cell lines were then derived from this population following single-cell dilution cloning. Cell lines were identified that gave robust GABA responses upon activation with 1 mM GABA (as determined using planar array electrophysiology-see later). A single clone, termed c3, was selected for all subsequent experiments. The presence of the γ-subunit was verified functionally by the presence of modulator responses to the benzodiazepine, zolpidem. Cells were routinely cultured in T175 flasks (Corning, Corning, NY) at subconfluency (<80%) in a humidified incubator at 37 °C, 5% CO 2 . Every 2 to 3 days, cells were split 1:3 with TrypLE (Invitrogen) to a density of 2 to 3 × 10 6 cells per flask.
Patch-clamp electrophysiology
GABA A α1β3γ2 expressing HEK cells were prepared for conventional patch-clamp recordings by first plating them at low density onto glass coverslips. Two to 4 h later, a single coverslip was placed into a small recording chamber, which was constantly perfused (1-2 mL min -1 ) with an external recording solution containing (ingredients in mM) 135 NaCl, 5.3 KCl, 1 MgCl 2 , 1.8 CaCl 2 , and 5 HEPES at pH 7.4, 305 mOsm at room temperature (20-25 °C) . Patch electrodes with tip resistances ranging from 4 to 7 MΩ were fabricated using a vertical puller (Narishige, Tokyo, Japan) and then filled with a prefiltered intracellular solution containing (ingredients in mM) 140 CsCl, 1 MgCl 2 , 11 EDTA, 10 HEPES at pH 7.35, and 295 mOsm. Voltage-clamp and data acquisition were performed using an Axopatch 200B (Axon Instruments, Union City, CA) amplifier coupled to pClamp control software (v10, Axon Instruments) via an analog to digital converter (Digidata 1440, Axon Instruments). Signals were prefiltered at a 5-kHz bandwidth and sampled at 1 kHz. All experiments were performed on cells with seal resistances of 1 to 10 GΩ and at a holding potential of -60 mV. GABA solutions in external buffer were applied via multibarreled, pressure ejection pipettes controlled by electromagnetic switch valves (Scientifica, Uckfield, UK), yielding switch latencies of <50 ms. After an initial stabilization period (>5 min), GABA (1 mM) was applied for 0.5 s followed by a 30-s washout recovery period. GABA was then reapplied at varying concentrations (3 µM to 1 mM), and the responses were normalized to the initial (1 mM) peak response.
Planar array electrophysiology
Planar array electrophysiology recordings were made on an IonWorks Quattro instrument enabled for both single-cell and population patch-clamp measurements. 22, 23, 25 Cell suspensions were created immediately prior to an experiment by first aspirating the growth media from the T175 flask and washing with 5 mL Ca/Mg free phosphate-buffered saline (PBS; Invitrogen). Cells were then treated with the cell dissociation agent TrypLE (2 mL) for 6 min at 37 °C and dislodged by tapping the flask. Following a short centrifugation step (700 rpm for 2 min), the cells were resuspended in 5 mL prefiltered (0.2 µm) external buffer (Dulbecco's PBS [Invitrogen] ingredients in mM NaCl 138, Na 2 HPO 4 -7H 2 O 8, KCl 2.67, KH 2 PO 4 1.47, MgCl 2 -6H 2 O 0.493, CaCl 2 0.901) and gently triturated for 1 min to yield a final density of ∼2 × 10 6 cells mL -1 . The cell suspension was then added to the cell reservoir on the instrument from which it was dispensed onto the Patch Plate. All recordings were made using an internal solution composed of (mM) K-Gluconate 140, EGTA 5, HEPES 5, MgCl 2 5, and CaCl 2 0.1 and 100 µM amphotericin. The base protocol allowed 5 min for the cells to seal to the substrate followed by a further 11 min to obtain the stable perforated patch-clamp configuration.
All recordings were made at room temperature (20-25 °C). Cells/wells were clamped in groups of 48 in either single-hole or population patch-clamp (PPC) mode using the electronics (E-) head held at -60 mV (with reference to a common "intracellular" ground electrode) for 10 s.
Step (300 ms, 0 mV) and ramp (300 ms, -80 mV to +60 mV) commands were then applied and the resulting currents sampled at 2.5 kHz. Leak subtraction was not employed (see Results). After this initial signal measurement (in the absence of ligand), the E-head was removed from the recording well, and GABA (or test compound) containing solution was added via a fluidics (F-) head dispenser. The F-head is then required to move away before the E-head can be positioned to reclamp and record from the cells. By using the "eighth of a plate" at once software configuration and applying test compounds in a volume of 5 µL without mixing, it was possible to measure compound-evoked currents only 8 s post compound addition.
Compounds and solutions
Compounds were obtained from the following sources: GABA, diazepam, pentobarbital Na, and bicuculline methiodide (all Sigma-Aldrich); zolpidem, propofol, chlormethiazole hydrochloride, gabazine hydrobromide, and picrotoxin (all Tocris, Ellisville, MO); tracazolate succinate (Research Biomedicals St. Louis, MO); and etomidate (MDA Chemicals, Lancaster, UK). Unless otherwise stated, compounds were initially solubilized to a concentration of 10 mM in 100% DMSO. Amphotericin solutions were made up fresh every day in DMSO (32 mM stock) and required sonication. Serial dilutions of GABA were made by hand in external PBS. For the IonWorks experiments, lowvolume (30 µL), 11-point, 3-fold serial dilutions were performed on a 384-well microplate (Greiner, Monroe, NC) in DMSO using a Biomek FX (Beckman Coulter, Fullerton, CA) liquidhandling device. Columns 6 and 18 were used as high (30 µM GABA final) and low (DMSO vehicle) controls in all cases. Then, 1-µL plate copies were stamped out onto fresh 384-well plates. Immediately prior to the experiment, 33 µL bulk volume of the external recording solution was added across the plate using a Multidrop Combi (Thermo, Waltham, MA) to yield serial dilutions in 3% DMSO. Allowing for the final 1:2 dilution in the patch plate, the final assay DMSO concentrations were 1.5%.
Data handling and analysis
Data analyses and graphical presentation were performed using a combination of IonWorks v2.0 (Molecular Devices, Sunnyvale, CA), Microsoft Excel (v5.0), Microcal Origin (v8), and pClamp (v10, Axon Instruments) software. All data are shown as arithmetic mean ± SE mean (n). Statistical analyses were performed using the Student t test.
For the IonWorks data, individual cells (single hole) or wells (PPC) that had seal resistances <50 MΩ (single hole) or 20 MΩ (PPC) and/or voltage offsets >±20 mV on the precompound read were excluded from subsequent analyses. Current amplitudes were measured from the step to 0 mV from each read and the drug-evoked signal calculated by subtracting the precompound from the postcompound amplitude. Concentration-response curves were fitted using a 4-parameter logistic equation of the form
where A 1 is the maximum asymptote, A 2 is the minimum asymptote, x 0 is the XC 50 , and p is the Hill slope. For the bicuculline and gabazine antagonist experiments, concentration ratios were determined for the shifts in the GABA curve from the pEC 50 values in the absence and presence of antagonist. A Schild linear regression was used to determine the pA 2 (intercept at log CR -1 = 1) and slope values. The Nernst equation was used to calculate the theoretical Clequilibrium potential:
where E x is the Clreversal potential, R is the universal gas constant, T is the absolute temperature in Kelvin, z is the valency of the ion, and F is the Faraday constant.
RESULTS
Conventional patch clamp
Rapid application of GABA (3-1000 µM) evoked concentration-related inward currents at -60 mV in GABA A α1β3γ2-HEK cells, ranging cell to cell from <100 pA to 10 nA peak amplitude at 100 µM (mean 3.8 ± 0.5 nA, n = 39; Fig. 1A) . The threshold concentration was 3 µM, and peak responses were generally observed at 100 to 300 µM. There was clear evidence of slow channel desensitization in the continued presence of GABA. From a pooled cell analysis of long GABA applications, the asymptote values of the 4-parameter logistic curve fits measured at 8 s (0.71 ± 0.05) and at 18 s (0.36 ± 0.04) after the start of the application were significantly lower than the corresponding peak responses (1.06 ± 0.07, p < 0.05; Fig. 1B ). There was no evidence for concentration-dependence of desensitization, as evidenced by the comparable pEC 50 values for GABA at each time point (4.7 ± 0.1, peak; 4.7 ± 0.1, 8 s; 4.7 ± 0.1, 18 s).
Planar array single-hole signals
In preliminary experiments, GABA A α1β3γ2-HEK cells sealed well to the recording substrate with mean seal resistances of 239 ± 114 MΩ (n = 364). From the precompound read, small linear currents were observed from a 300-ms voltage ramp from -80 to +60 mV that reversed close to 0 mV ( Fig. 2A) . These currents most likely represent the nonbiological (nonsubtracted) leak rising from the comparatively low seal resistances. Importantly, these currents were extremely small at 0 mV (<50 pA), a potential at which the nonbiological leak should always be 0 (assuming any liquid junction potential offsets have been suitably corrected for-see John et al. 25 for further explanation of similar concepts). In wildtype cells, application of GABA (up to 1 mM) had no significant effect at any potential across the voltage ramp (data not shown). In the GABA A α1β3γ2-HEK cells, resistances were stable over time (mean absolute difference post-pre 35 ± 14 MΩ), and buffer addition or 1.5% DMSO did not evoke any responses (data not shown). In contrast, application of GABA (100 µM) evoked a marked left shift in the currentvoltage relationship and increase in slope conductance ( Fig.  2A) . Subtracting the precompound signal from the postcompound signal yielded the I GABA , which was linear, and reversed at -48 mV, close to the Clequilibrium potential (-56 mV; Fig. 2A ). There was considerable heterogeneity in the amplitude of the I GABA from cell to cell; the outward current ranged from 0 pA to >7 nA at 0 mV (Fig. 2B) . The fraction of "responders," defined as cells in which GABA evoked >100 pA current at 30 µM, was 50% to 60%. Attempts to generate concentration-response curves to GABA in single-hole mode were confounded by this cell-to-cell variation and were unsuccessful (see John et al. 25 )
Planar array PPC signals
In PPC mode, the seal resistances were generally lower, ranging from 31 to 101 MΩ (mean 73 ± 13 MΩ, n = 41 plates). As anticipated, the measurement of an ensemble "average" signal from a population of (up to 64) cells yielded measurable GABA-evoked currents in every case, which were highly consistent well to well (mean 2.19 ± 0.26 nA at 0 mV; Fig. 2C ). In vehicle (DMSO)-treated wells, there was no significant response (mean 0.01 ± 0.01 nA at 0 mV; Fig. 2C ). Mean Z′ values of 0.51 (range, 0.26-0.66) were determined for these high (30 µM GABA) and low (1.5% DMSO) control wells from 19 patch plates. 26
Agonist and modulator pharmacology
With the added consistency and precision of PPC, it proved possible to construct robust agonist concentration-response curves. GABA, muscimol, and isoguvacine each evoked concentration-dependent outward currents at 0 mV that, when fitted to a 4-parameter logistic equation, displayed similar maxima and Hill slopes (Table 1 and Fig. 3A,B) . The observed rank order of agonist potency was muscimol > GABA > isoguvacine with mean pEC 50 values of 5.9 ± 0.1, 5.4 ± 0.1, and 4.4 ± 0.1, respectively (n = 10-12). To characterize positive modulators, we coapplied an EC 20 concentration of GABA (1 µM) with the compound of interest. The benzodiazepines diazepam and zolpidem both elicited concentration-dependent augmentation of the GABA-evoked current (3-to 5-fold) with modulator pEC 50 values of 7.0 ± 0.3 and 6.8 ± 0.2, respectively ( Fig. 3C) . Tracazolate and pentobarbital, 2 structurally distinct nonbenzodiazepine modulators, were also active with modulator pEC 50 values of 5.3 ± 0.1 and 4.5 ± 0.2, respectively (Fig. 3D) . The specific benzodiazepine site antagonist flumazenil (10 µM) had no effect on the GABA response per se but attenuated the modulation by zolpidem but not pentobarbital (Fig. 4A,B) . A range of other benzodiazepine and nonbenzodiazepine positive modulators were also active, including propofol, etomidate, flunitrazepam, clonazepam, chlormethiazole, and chlordiazepoxide ( Table 1) .
Antagonist pharmacology
The effects of putative GABA antagonists were evaluated by coadministering the compounds with GABA. In initial studies, using an EC 80 concentration of GABA, gabazine, bicuculline, and picrotoxin each produced concentration-related and complete inhibition ( Fig. 5D ) with mean pIC 50 values of 6.7 ± 0.2, 5.6 ± 0.2, and 5.6 ± 0.1, respectively (n = 6). The Hill slopes were 1.4 ± 0.3, 1.7 ± 0.3, and 1.2 ± 0.2, respectively. To delineate mechanisms of block, we then determined concentration-response curves (CRCs) to GABA in the presence of different antagonist concentrations. Both gabazine (0.1-100 µM) and bicuculline (0.4-100 µM) produced concentration-dependent, rightward displacement of the GABA CRC without depression of the maximal response (Fig. 5A) . Schild regression yielded pA 2 values of 6.7 for gabazine and 5.7 for bicuculline, each with slope values of 1.0, consistent with competitive antagonism (Fig. 5B) . In contrast, picrotoxin markedly suppressed the maximum of the GABA CRC and produced small rightward displacements, indicating a noncompetitive mode of antagonism (Fig. 5C) .
Small-scale screen
To assess the suitability of the developed protocols for screening novel compounds for GABA A activity, we profiled a set of 700 compounds at a single concentration (10 µM) in agonist, positive modulator, and antagonist modes. From 4 plates in agonist mode, Z′ values (DMSO vehicle vs. 30 µM GABA) of 0.56, 0.20, 0.59, and 0.54 were obtained. From this set, we did not detect any previously unknown compounds with agonist activity >10% of that of GABA (30 µM) when tested on 2 separate occasions (Fig. 6A,D) . In positive modulator format, as anticipated, the assay precision was slightly lower (Z′ values of 0.13, 0.31, 0.35, and 0.28) due to a greater variance around the EC 20 agonist + vehicle "low control." Nevertheless, 2 active samples were identified that each produced >20% augmentation of the EC 20 response on 1 or more test occasions, corresponding to a 0.3% hit rate (Fig. 6B,E) . In the antagonist format, Z′ values of 0.60, 0.51, 0.50, and 0.55 were obtained. Twenty-one compounds produced >40% block on 1 or both test occasions (Fig. 6C,F) , corresponding to a hit rate of 3.0%. The most active compound (80% block at 10 µM, n = 2) was followed up and shown to be a novel competitive antagonist with a pA 2 value of 6.1. By conventional patch clamp, the same compound abolished GABA (100 µM) responses when preincubated for 10 min at a concentration of 30 µM (85 ± 6% inhibition, n = 4).
DISCUSSION
The major finding of this study is that PPC appears, empirically at least, to offer a novel valuable high-throughput electrophysiology method for screening and profiling compounds at GABA A receptors.
Several lines of evidence support the contention that specific, relevant signals can be studied using this approach. GABA evoked signals only in cells transfected with recombinant GABA A subunits-the drug vehicle (1.5% DMSO) had no effect per se, and untransfected wild-type cells were not responsive. In high-throughput mode, from cell to cell there was significant heterogeneity in the amplitude of the response ranging from 0 to +7 nA at 0 mV, which we attribute primarily to varying levels of expression (see John et al. 25 ). Another contributory factor could be different rates of desensitization. With the current design of the recording system (48-channel E-and F-head), the minimum interval between application of GABA and the recording of the ramp current is 8 s. From our conventional electrophysiology recordings, however, the extent of desensitization between cells was reasonably consistent (30%-40% at this time point), indicating that desensitization is not a major component. The PPC configuration significantly reduced the heterogeneity in well-to-well signal amplitude (coefficient of variation [CV] <10%), as predicted from the theory of averaging and from experiences with other channels. 23, 25, 27 This is enabling because it allows meaningful and direct well-to-well signal comparisons. Current voltage-relationships for the isolated GABA response were largely as expected for a gated Clconductance under the ionic conditions; I GABA reversed close to the theoretical Clequilibrium potential (-48 mV vs. -56 mV) and showed limited rectification. Importantly, the I GABA values determined at 0 mV should not be contaminated by changes in seal resistance (nonbiological leak conductance) because this is the potential at which I leak will itself be close to 0. Overall, these observations provide confidence that the outward I GABA at 0 mV under the experimental conditions is a specific, receptormediated signal that is not contaminated by other biological or nonbiological measures.
This conclusion is further supported by the observed pharmacology. GABA produced concentration-dependent responses with a pEC 50 value of 5.4, some 0.7 log units greater than that observed by conventional electrophysiology. The explanation for this small disparity is presently unclear but could be due to the significant methodological differences between the 2 approaches. The PPC signal is a discontinuous voltage-clamp multicell record made on a chip in the perforated patch-clamp configuration, where GABA is applied by a 1:2 volume dilution method. In contrast, we use continuously clamped wholecell recording via glass microelectrodes for the conventional electrophysiology, and GABA is applied by ultra-rapid solution exchange. The extent to which these or other methodological differences (e.g., cell suspension vs. adherent) truly contribute is very hard to predict or determine. It could be argued that the pEC 50 appears artificially high in PPC because the upper asymptote of the concentration-response curve is underestimated due to desensitization-this, however, seems unlikely because we have shown that the pEC 50 value determined by conventional electrophysiology is independent of the time at which the signal is measured (peak, 8 s, 18 s) and that there is no overt concentration dependence to the kinetics of desensitization. Moreover, if the upper asymptote was underestimated, a steep Hill slope would have been expected-in all of our experiments, we never observed slopes greater than the value of 2, predicted by the requirement for 2 agonist molecules to bind to activate the channel. 28 Interestingly, the known GABA agonists muscimol and isoguvacine were also approximately 0.5 log units more potent in PPC compared to literature patchclamp measurements with similar receptor subunits. 29, 30 The rank order of potency (muscimol > GABA > isoguvacine) was the same in each case. A number of known positive modulator compounds augmented responses to a coapplied EC 20 of GABA but did not exhibit agonist effects per se. The BDZs zolpidem, 31 diazepam, 32 flunitrazepam, and clonazepam (for review, see Atack 33 ) evoked small (100%-200%) but measurable potentiating effects, with potencies generally comparable to published literature values with human α1β2γ2 cell lines. 32, 34 These findings verify functionally the expression of the γ subunit in our cell line because the known BDZ recognition site is at the α/γ subunit interface. 35 The non-BDZ modulators pentobarbital, tracazolate, propofol, etomidate, chlormethiazole, and chlordiazepoxide were also active. Although small differences were noted between the modulator potencies in the PPC and literature values, generally the profile was as previously described (see Table 1 for references). Flumazenil, a BDZ site antagonist, abolished the effect of zolpidem but did not attenuate responses to pentobarbital, a barbiturate site modulator. 36 Antagonism of GABA responses could also be clearly demonstrated. When coapplied with GABA, both bicuculline and gabazine produced concentration-dependent rightward displacements of the GABA concentration-response curve with no evidence of depression of the maxima. This profile and the unitary slope of the Schild plot confirm a competitive interaction between these antagonists and GABA, consistent with other functional and binding studies. 37, 38 In contrast, picrotoxin suppressed the maxima and produced small lateral displacements of the GABA curve as anticipated from its noncompetitive, pore-blocking mechanism of action. [39] [40] [41] [42] As with the agonists and positive modulators, the potencies of all 3 antagonists were similar to those observed with conventional electrophysiology ( Table 1) . Indeed, if our PPC pharmacology in toto is compared to literature values, an excellent correlation coefficient of 0.88 would be observed.
Despite these findings, evidently a number of theoretical limitations of the PPC method for quantifying the pharmacology of slow-ligand gated channels (e.g., GABA A α1β3γ2) need to be considered. First, by measuring the signal at a single point 8 s after ligand application, the method is susceptible to any differences in the rate of desensitization either between agonists or for the same agonist at different concentrations. Although there was limited evidence of a concentration dependence to desensitization for GABA with the α1β3γ2 subunit combination (from conventional patch clamp), this cannot be assumed for all agonists and for all channels. Indeed, for many ligandgated channels, it has been shown that desensitization proceeds more rapidly at higher ligand concentrations. A similar constraint can be argued for modulators; modification of the kinetics of desensitization is a key mechanism of action of some but not all modulating compounds. For these reasons, areas under the curve or total charge transfer analyses are often employed with conventional patch clamp. For ligand-antagonists or pore blockers, time-dependent effects are also possible if either equilibrium has not been achieved or block is dependent on a gating event (e.g., open channel block). Of course, the PPC approach we describe would be totally unsuitable for ligand-gated events that decay to such an extent before the 8-s detection time point so as to be immeasurable (e.g., nACh7 receptors, P2X1/3 receptors). Conversely, where it could be most valuable in the ligand-gated channel setting is for channels that exhibit little or no desensitization (e.g., TRPV1, P2X7, 5-HT 3 ). Were it possible to design an integrated fluidics and read head so that compounds could be applied in real time, then any limitations of the delayed signal read could be eliminated entirely.
Importantly, the true extent of the theoretical limitations outlined above is best considered in the context of other available methods for ligand-gated channel screening. With the exception of conventional patch clamp, which is slow and labor intensive, there is no other detection method that permits ultrarapid (ms) ligand application. All other approaches thus suffer the same inability as PPC to make real-time measurements that are devoid of the complexities of fast desensitization. Fluorescence-based flux (e.g., Cl -YFP for GABA A ) or membrane-potential measures provide useful high-throughput hit identification assay formats but suffer from nonlinearity of signal and auto-fluorescence and quenching artifacts that limit their use in secondary screening and structure-activity relationship (SAR) work. Medium-throughput voltage-clamp electrophysiology at least provides a direct readout of ion channel function that is not susceptible to nonlinear pharmacology or false-positive hits. With the possibility to generate 2000 to 3000 data points (single drug concentration, n = 1) per day per instrument, PPC offers a throughput of at least 100-fold greater than conventional electrophysiology.
In summary, we find that the complex pharmacology of GABA A α1β3γ2 receptors can be readily confirmed with PPC and with a throughput commensurate with SAR screening and small-scale hit identification work. We therefore believe that PPC affords a useful addition to the armory of the ligand-gated ion channel pharmacologist.
